| 货号 | 14270-1g |
| 描述 | Rivastigmine is an irreversible inhibitor of acetylcholinesterase (IC50 = 4.15 µM) and butyrylcholinesterase (IC50 = 37 nM).1,2 It acts by covalently modifying a serine residue in the active site by carbamoylation.3 Rivastigmine has found use in modifying the course of neurodegenerative diseases, including Parkinson’s disease and Alzheimer’s disease, as it stabilizes or reduces the rate of decline in certain cognitive functions.4,5,6 |
| 别名 | Exelon;SDZ-ENA 713; |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Yu, Q.S.,Zhu, X.,Holloway, H.W., et al. Anticholinesterase activity of compounds related to geneserine tautomers. N-oxides and 1,2-oxazines. J. Med. Chem. 45(17), 3684-3691 (2002). 2.Luo, W.,Yu, Q.S.,Kulkarni, S.S., et al. Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (−)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine. J. Med. Chem. 49(7), 2174-2185 (2006). 3.Muñoz-Torrero, D. Acetylcholinesterase inhibitors as disease-modifying therapies for Alzheimer’s disease. Curr. Med. Chem. 15, 2433-2455 (2008). 4.Baskys, A. and Hou, A.C. Vascular dementia: Pharmacological treatment approaches and perspectives. Clinical Interventions in Aging 2(3), 327-335 (2007). 5.Grossberg, G.,Cummings, J.,Frölich, L., et al. Efficacy of higher dose 13.3 mg/24 h rivastigmine patch on instrumental activities of daily living in patients with mild-to-moderate Alzheimer’s disease. Am.J.Alzheimers Dis.Other Demen. 28(6), 583-591 (2013). 6.Possin, K.L.,Kang, G.A.,Guo, C., et al. Rivastigmine is associated with restoration of left frontal brain activity in Parkinson’s disease. Mov.Disord. 28(10), 1384-1390 (2013). | |
| 运输条件 | Room temperature in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥95% |
| 计算分子量 | 400.4 |
| 分子式 | C14H22N2O2 • C4H6O6 |
| CAS号 | 129101-54-8 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |